BlackRock, Inc. 13D and 13G filings for BridgeBio Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-12 11:44 am Unchanged | 2024-09-30 | 13G | BridgeBio Pharma, Inc. BBIO | BlackRock Inc. BLK | 12,878,839 6.800% | 0 (Unchanged) | Filing |
| 2024-10-22 6:06 pm Purchase | 2024-09-30 | 13G | BridgeBio Pharma, Inc. BBIO | BlackRock Inc. BLK | 12,878,839 6.800% | 2,722,066 (+26.80%) | Filing |
| 2024-01-29 5:25 pm Purchase | 2023-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | BlackRock Inc. BLK | 10,156,773 5.800% | 322,372 (+3.28%) | Filing |
| 2023-01-31 5:52 pm Purchase | 2022-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | BlackRock Inc. BLK | 9,834,401 6.600% | 558,811 (+6.02%) | Filing |
| 2022-02-03 4:41 pm Purchase | 2021-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | BlackRock Inc. BLK | 9,275,590 6.300% | 2,758,046 (+42.32%) | Filing |
| 2021-02-05 07:51 am Purchase | 2020-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | BlackRock Inc. BLK | 6,517,544 5.300% | 6,517,544 (New Position) | Filing |